The evolving landscape of enzymatic technologies for precision synthesis of antibody–drug conjugates
Antibody Therapeutics · 29.06.2026 · 9 (3) · 259-272
DOI: 10.1093/abt/tbag020 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Antibody Therapeutics, online erschienen am 29.04.2026. Verfasst von Thuc Oanh Hoang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Pharmaceutical Sciences, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern Califor…. Die Arbeit nennt 148 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIBIB NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Precise control over how and where small-molecule drugs are covalently attached to monoclonal antibodies is increasingly vital for creating consistently efficacious and safe antibody–drug conjugates (ADCs) as powerful targeted therapies. Enzymatic conjugation methods have gained considerable attention for their abilities to efficiently install payloads at defined locations under mild and predictable conditions. This work provides a comprehensive review of current enzymatic technologies for site-specific ADC construction, organized by the biological origin of enzymes. Among various enzyme-based conjugating approaches, a special focus is given to the emerging ADP-ribosyl cyclase–enabled ADC (ARC-ADC) platform. By utilizing genetically fused CD38, a member of the ARC family, together with its dinucleotide-derived inhibitor, site-specific ADCs with defined drug-to-antibody ratios in varied formats could be facilely produced with demonstrated efficacy and specificity in preclinical models of different types of cancer. Unlike most enzymatic methods requiring recognition tags or external catalytic steps, ARC-ADC provides a fully integrated, modular strategy for streamlined ADC discovery and development.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology and Pharmaceutical Sciences, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, United States.
- Department of Chemistry, Dornsife College of Letters, Arts and Sciences, University of Southern California, Los Angeles, CA 90089, United States.
- Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90089, United States.
- Research Center for Liver Diseases, University of Southern California, Los Angeles, CA 90089, United States.
ORCID-Profile: Yong Zhang
Förderung
- NCI NIH HHS
- NIBIB NIH HHS
- NIGMS NIH HHS
- National Institute of General Medical Sciences
- National Institutes of Health
- National Institute of Biomedical Imaging and Bioengineering
- National Cancer Institute
Zitieren
APA
Hoang, T. O., Ansari, A. J., & Zhang, Y. (2026). The evolving landscape of enzymatic technologies for precision synthesis of antibody–drug conjugates. Antibody Therapeutics, 9(3), 259-272. https://doi.org/10.1093/abt/tbag020
Vancouver
Hoang TO, Ansari AJ, Zhang Y. The evolving landscape of enzymatic technologies for precision synthesis of antibody–drug conjugates. Antibody Therapeutics. 2026;9(3):259-272. doi:10.1093/abt/tbag020
BibTeX
@article{Hoang2026,
author = {Hoang, Thuc Oanh and Ansari, Arshad J and Zhang, Yong},
title = {The evolving landscape of enzymatic technologies for precision synthesis of antibody–drug conjugates},
journal = {Antibody Therapeutics},
year = {2026},
volume = {9},
number = {3},
pages = {259--272},
doi = {10.1093/abt/tbag020}
}
EUVIMED